Moderna Inc at SVB Leerink Global Healthcare Conference (Virtual) Transcript
Hello. It's Mani Foroohar, a senior analyst focused on genetic medicines here at SVB Leerink. And I'm very fortunate on the heels of this morning's earnings call and updated announcements to have Tal Zaks joining us from Moderna. How are you doing this morning, Tal?
Very well, Mani. Thanks for having me.
Obviously, it's been an eventful year, eventful morning, including your transition to eventually another role in the future. Congratulations on a remarkable run over the course of last year, especially. In case people have not noticed, it has been eventful for the vaccine space and Moderna specifically. But before we dive straight into Q&A as I'm sure a lot of investors will have questions, as a reminder, for those in the audience, if you want to send a
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |